Trilaciclib

Trilaciclib (CAS No.: 1374743-00-6) is a potent, selective, and reversible cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor that inhibits the activity of the CDK4/cyclin D1 and CDK6/cyclin D3 complexes, with IC50 values of 1 nM and 4 nM, respectively. By transiently inducing G1-phase cell-cycle arrest, Trilaciclib can protect hematopoietic stem and progenitor cells from chemotherapy-induced DNA damage and apoptosis, thereby alleviating chemotherapy-related myelosuppression. In vitro studies show that Trilaciclib effectively inhibits CDK4/6 activity in the nanomolar to low micromolar range. In animal models, Trilaciclib reversibly regulates the proliferation of hematopoietic stem and progenitor cells in the bone marrow of mice and dogs in a dose- and time-dependent manner. The dose or concentration used in experiments typically depends on the experimental design and research objectives.